GK01 autologous tumor-reactive T cells (TCR T-cells)

drug_type

RELEVANT_DRUG

intervention_type

Cellular therapy

drug_description

Autologous adoptive T-cell therapy in which patient-derived tumor-reactive T cells are expanded ex vivo and reinfused to recognize peptide-HLA complexes via native T-cell receptors, activating cytotoxic effector functions (perforin/granzyme and cytokines) to kill tumor cells.

nci_thesaurus_definition

NCI thesaurus definition not available.

drug_mesh_term

Lymphocytes, Tumor-Infiltrating

drug_category

TUMOR INFILTRATING LYMPHOCYTES

drug_class

Unedited cells

drug_delivery_route

Intravenous

drug_mechanism_of_action

Autologous tumor-infiltrating T cells are expanded ex vivo and reinfused to recognize tumor peptide–HLA complexes via their native T‑cell receptors, triggering TCR signaling and cytotoxic effector functions (perforin/granzyme release and cytokine secretion) to kill tumor cells.

drug_name

GK01 autologous tumor-reactive T cells (TCR T-cells)

nct_id_drug_ref

NCT06431100